CD8A and neoplasm: In this study, the addition of PF-04136309 to FOLFIRINOX did not enhance toxicity of therapy, but resulted in reduction in the TAM infiltrate, increased the amount of CD8+ and CD4+ cells, reduced the presence of Tregs, and induced an endogenous anti-tumor immune response [82].